Detailed performance report for WATERS CORPORATION covering Q3 2025. Gain clarity on earnings, revenue trends, and AI-enhanced strategic analysis.
Summary of Financial Performance: Waters Corporation reported a strong third quarter of 2025 with sales increasing by 8% both as reported and in constant currency. Instrument sales grew by 6%, and recurring revenue increased by 9%, driven by service growth (7%) and chemistry growth (13%). Non-GAAP earnings per share rose by 16% to $3.40, exceeding guidance by $0.20. The company achieved a gross margin of 59% and an adjusted operating margin of 30.3%. Free cash flow was $160 million, with net debt at $948 million.
Company Outlook & Strategy: Waters Corporation raised its full-year 2025 guidance, expecting constant currency sales growth between 6.7% and 7.3%, with adjusted EPS projected between $13.05 and $13.15. Looking to 2026, the company anticipates continued momentum driven by instrument replacement, innovation, and strategic acquisitions, including the pending combination with BD's Biosciences & Diagnostic Solutions business.
Key Industry Trends: The company is benefiting from global trends such as the increased demand for GLP-1 testing, PFAS testing, and growth in the India generics market. Additionally, new FDA guidance favoring analytical testing for biosimilars could drive future demand for Waters' bioanalytical characterization instruments.
Operational Highlights: Waters launched the Xevo CDMS, marking a significant advancement in mass spectrometry for large molecule therapeutics. The company also saw strong adoption of its new chemistry products like SEC and Affinity Bioseparation Columns. The integration planning for BD's business is underway, with synergies expected to be realized shortly after the transaction's completion.
Challenges & Risks: While Waters has experienced strong growth, certain segments like CROs, biotechs, and branded generics in China remain slow. The company is cautious about potential air pockets following stimulus-related academic spending in China.
Key Analyst Questions & Responses: Analysts inquired about the sustainability of pharma strength in various regions, including the U.S. and China, and the impact of new FDA biosimilar guidance on Waters' business. Management highlighted robust pharma growth driven by product innovations and strategic execution. Analysts also questioned the potential revenue synergies from the BD acquisition, to which management expressed confidence in achieving accretive synergies through improved service offerings and leveraging existing channels.
Access the official earnings call transcript for WATERS-CORPORATION 2025 Q3. It provides valuable insights into management commentary, performance drivers, and forward-looking guidance directly from the company.